LMAT — LeMaitre Vascular, Inc.

Summary of LeMaitre Vascular Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025 sales grew 16% year-over-year, with organic revenue growth of 15%.
• Gross margin improved to 71.7%, up 240 basis points from the previous year.
• Operating income increased by 47% to $18.8 million, resulting in an operating margin of 29%.
• Fully diluted EPS for Q4 was $0.68, a 39% increase year-over-year.
• For the full year 2025, revenue grew 14%, with adjusted EPS growth of 23%.
• Ended 2025 with $359 million in cash and securities; free cash flow for the year was $74.5 million.

2. Strategic Updates and Business Highlights:

• Strong sales growth driven by grafts (up 27%), valvulotomes (up 20%), and shunts (up 18%).
• International sales of Artegraft reached $4 million in 2025, with expectations of $10 million in 2026.
• Plans to expand direct sales into Poland and increase the sales force from 160 to 170-180 by the end of 2026.
• Consolidation of the Chicago RFA facility into Burlington aimed at simplifying operations and reducing costs.
• The company has a new $100 million share repurchase program and a 25% increase in the quarterly dividend.

3. Forward Guidance and Outlook:

• For 2026, LeMaitre anticipates revenue of $280 million, representing 12% organic sales growth.
• Expected adjusted operating income growth of 21% to $77.8 million, with EPS projected at $2.91, up 22%.
• Gross margin guidance for 2026 is set at 72.1%.

4. Bad News, Challenges, or Points of Concern:

• A cyber incident in January 2026 had minimal impact on operations but is under review for potential risks.
• The transition of manufacturing from Chicago to Burlington may pose short-term headwinds to gross margins.
• Competitive pressures from larger companies and regulatory challenges in the market remain ongoing concerns.

5. Notable Q&A Insights:

• Management emphasized the importance of maintaining operating leverage through stable headcount and pricing strategies.
• The smooth implementation of price increases in 2026 was attributed to earlier communication with stakeholders.
• Artegraft's performance exceeded expectations, with a revised total addressable market (TAM) in Europe now estimated at $30 million.
• The company is actively pursuing M&A opportunities, particularly in the open vascular and cardiac surgery markets, with a focus on finding the right acquisitions rather than just larger ones.
• Questions about the impact of the CREST-2 trial on carotid artery stenting business indicated resilience in their carotid shunt sales despite potential market shifts.

Overall, LeMaitre Vascular demonstrated strong financial performance and strategic growth initiatives while navigating potential challenges and competitive pressures in the market.